Trial Profile
A phase I dose escalation study of Apatinib in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2016
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- 27 Apr 2016 New trial record